Amber Salzman

Amber is the CEO of a stealth gene regulation company and sits on the Board of Aviado Bio, a gene therapy company, and Biotechnology Innovation Organization, an association that represents the biotechnology industry.

Amber began her career at GlaxoSmithKline where she was responsible for clinical trials globally with 30,000+ active patients, directing a budget of $1.25B and 1,600 employees worldwide. She then served as CEO of Cardiokine, until its sale to Cornerstone Therapeutics. After Cardiokine, Amber launched Annapurna, a gene therapy company that merged with Avalanche (NASDAQ:AAVL) to create Adverum Biotechnologies (NASDAQ:ADVM). After serving as CEO for Adverum, Amber returned to the east coast to lead Ohana Biosciences, a Flagship Pioneering company, establishing the industry’s first sperm product platform. Concurrent with industry positions, Amber leads a non-profit medical research foundation focused on accelerating the development of therapies for adrenoleukodystrophy (ALD).

Amber received a PhD in Mathematics from Bryn Mawr College in Pennsylvania, and a degree in Computer Science from Temple University in Philadelphia.